ARTICLE | Company News
Novartis drops Novo's NN622
October 29, 2001 8:00 AM UTC
Novartis (NVS; SWX:NOVN) ended a July deal with Novo Nordisk (NVO) to commercialize NVO's Type II diabetes treatment NN622, a PPAR (peroxisome proliferator-activated receptor) alpha and gamma antagoni...